Emerging concepts in metabolic abnormalities associated with coronary artery disease

Current Opinion in Cardiology

Volumn 15, Issue 6, 2000, Pages 416-421

  Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRIACYLGLYCEROL; TROGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ANIMALS; CORONARY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; TRIGLYCERIDES;

EID: 0033695265     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200011000-00008     Document Type: Review

References (54)

1. Historical review of research on atherosclerosis
2. Anitschkow and the cholesterol over-fed rabbit
3. The Nobel chronicles
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
6. Epidemiology of type 2 diabetes: Risk factors
7. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators
8. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications
9. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study)
10. Diabetes mellitus and cardiovascular disease in women
11. Risk factors for coronary heart disease in diabetes
12. Cardiovascular risk factors and the prediabetic syndrome
13. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
14. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
15. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
16. Banting Lecture 1988. Role of insulin resistance in human disease
17. Insulin resistance implications for type II diabetes mellitus and coronary heart disease
18. Insulin resistance: Current concepts
19. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit?
20. Pathophysiology of insulin resistance in human disease
21. Patients with type 2 diabetes: The case for primary prevention
22. Epidemiology of insulin resistance and its relation to coronary artery disease
23. Clinical review 102: Type 2 diabetes mellitus. Update on diagnosis, pathophysiology, and treatment
24. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
25. Impaired glucose tolerance, insulin resistance and cardiovascular disease
26. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study
27. Metabolic risk factors for coronary heart disease: Current and future prospects
28. Muller: The effect of age on insulin resistance and secretion
29. Treatment of diabetic dyslipidemia
30. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
31. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: A clue to the explanation of the results of the BARI study
32. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: Implications for the prevention of coronary heart disease
33. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
34. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
35. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study
36. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
37. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
38. Implications of the UK prospective diabetes study: Questions answered and issues remaining
39. The sulfonylurea controversy: More questions from the heart
40. Pharmacologic therapy for type 2 diabetes mellitus
41. Thiazolidinediones
42. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering
43. Thiazolidinediones: Tools for the research of metabolic syndrome X
44. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
45. Atherosclerotic plaque rupture: Emerging insights and opportunities
46. Peroxisome proliferator-activated receptors in the cardiovascular system
47. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
48. PPARgamma in monocytes: Less pain, any gain?
49. Another potential use of troglitazone in non-insulin dependent diabetes mellitus
50. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
51. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
52. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
53. Abciximab reduces mortality in diabetics following percutaneous coronary intervention